Form 4: Celldex Therapeutics Executive Granted Significant Stock Options to Align Incentives

Ronald Pepin, Senior Vice President and Chief Business Officer of Celldex Therapeutics, Inc., was granted 20,000 incentive stock options with an exercise price of $19.53, vesting over four years.

Summary

• Ronald Pepin, SR. VP & CBO of Celldex Therapeutics, Inc. (CLDX), received a grant of 20,000 Incentive Stock Options.
• The options have an exercise price of $19.53 per share.
• The grant was made on June 5, 2025, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan.
• The options begin vesting on June 5, 2026, with 25% vesting on that date, and the remaining portion vesting quarterly in equal amounts over the subsequent 12 quarters.
• The options have an expiration date of June 5, 2035.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the grant of stock options aligns executive incentives with shareholder value, which is generally viewed favorably. It's a routine compensation event, not indicative of major operational changes.

Positives

• The grant of incentive stock options aligns the interests of Senior VP & CBO Ronald Pepin with those of shareholders, as the value of the options is tied to the company's stock performance.
• The options were granted under an existing and approved plan (2021 Omnibus Equity Incentive Plan), indicating a structured approach to executive compensation.

Future Outlook

The granted incentive stock options will vest over a period of approximately four years, with the first 25% vesting on June 5, 2026, and the remainder vesting quarterly over the subsequent 12 quarters, providing a long-term incentive for the executive.

Industry Context

This Form 4 filing reflects a routine executive compensation event within the biotechnology or pharmaceutical industry, where stock options are a common tool to incentivize senior management and align their performance with shareholder value. Such grants are standard practice for publicly traded companies like Celldex Therapeutics.

Corporate Governance

Related Party Transactions

• The grant of 20,000 Incentive Stock Options to Ronald Pepin, a Senior Vice President and Chief Business Officer, constitutes a related party transaction as it involves compensation from the company to an executive officer.

Stakeholder Impact

• Shareholders: Potential positive impact if the options incentivize the executive to drive company performance and increase stock value.
• Employees: No direct impact on general employees, but it highlights the company's executive compensation strategy.
• Executive (Ronald Pepin): Direct positive impact through potential future equity ownership and wealth creation tied to company performance.

Next Steps

• The granted options will begin their vesting schedule on June 5, 2026, with subsequent quarterly vesting periods.

Key Dates

Recommendation

Keywords

Celldex Therapeutics, CLDX, Stock Options, Incentive Stock Option, Executive Compensation, Form 4, SEC Filing, Ronald Pepin, Equity Incentive Plan